Indegene Builds Tech Suite, Outcomes Play With Skura Deal
Executive Summary
Healthcare solutions provider Indegene expects its acquisition of Skura Corporation's life science business to expand its multi-channel technology suite and scale up product development capabilities in North America, positioning it for leadership in the "Outcome-as-a-Service" category.
You may also be interested in...
Asia Deal Watch: Astellas Looks To Vector Cell Tech From Japan’s RiKen In Oncology
RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.
Backed By Big Names, Etherna Hopes To Disrupt mRNA Space
Belgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.
Immuneel COO On Benchmarking The Firm’s CAR-T Against Mature, Global Data Sets
Immuneel’s COO, Dr Arun Anand, talks to Scrip about how things are shaping for the Indian start-up’s autologous CD19 directed CAR-T cell therapy and the ‘journey to be traversed’ on the pricing front. He believes India could potentially see cell therapies being commercialized in the next 12 to 18 months.